文献速递认知障碍与痴呆

血清可溶性髓样细胞触发受体2作为新发痴呆的生物标志物:久山研究

Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study.
PubMed 文献 · Ann Neurol · 2018-12-28

久山研究前瞻性随访1349名60岁以上无痴呆日本社区居民10年(2002-2012),采用酶联免疫吸附法检测血清sTREM2并四分位分组,Cox比例风险模型分析显示血清sTREM2最高四分位组较低四分位组全因痴呆、阿尔茨海默病和血管性痴呆风险均显著升高。

要点

  • 血清sTREM2最高四分位组较低四分位组全因痴呆风险升高(HR=2.03,95%CI 1.39-2.97,p<0.001)。
  • 血清sTREM2最高四分位组较低四分位组阿尔茨海默病风险升高(HR=1.62,95%CI 1.02-2.55,p=0.04)。
  • 血清sTREM2最高四分位组较低四分位组血管性痴呆风险升高(HR=2.85,95%CI 1.35-6.02,p=0.006)。

核心结论

  • 研究提示在普通老年日本人群中,血清sTREM2水平升高与全因痴呆、阿尔茨海默病和血管性痴呆的发病风险存在显著关联。

研究设计与样本

  • 前瞻性队列研究,纳入1349名60岁及以上无痴呆的日本社区居民,随访10年(2002-2012)。
  • 采用酶联免疫吸附法检测血清sTREM2水平并按四分位分组,使用Cox比例风险模型估计痴呆风险的风险比(HR)。

主要发现

  • 随访期间300例发生全因痴呆,其中193例为阿尔茨海默病,85例为血管性痴呆。
  • 年龄和性别调整后,全因痴呆、阿尔茨海默病和血管性痴呆的发病率均随血清sTREM2水平升高而显著升高(趋势检验均p<0.012)。
  • 调整包括高敏C反应蛋白在内的混杂因素后,上述关联未改变。
  • 血清sTREM2最高四分位组较低四分位组多变量调整后全因痴呆风险升高(HR=2.03,95%CI 1.39-2.97,p<0.001)。
  • 血清sTREM2最高四分位组较低四分位组阿尔茨海默病风险升高(HR=1.62,95%CI 1.02-2.55,p=0.04)。

关键数值与推荐

  • 血清sTREM2最高四分位组较低四分位组全因痴呆多变量调整HR=2.03(95%CI 1.39-2.97,p<0.001)。
  • 血清sTREM2最高四分位组较低四分位组阿尔茨海默病多变量调整HR=1.62(95%CI 1.02-2.55,p=0.04)。
  • 血清sTREM2最高四分位组较低四分位组血管性痴呆多变量调整HR=2.85(95%CI 1.35-6.02,p=0.006)。
  • 年龄和性别调整后全因痴呆、阿尔茨海默病和血管性痴呆发病率随血清sTREM2水平升高而显著升高(趋势检验均p<0.012)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between serum soluble triggering receptor expressed on myeloid cells 2 (sTREM2), a soluble type of an innate immune receptor expressed on the microglia, and the risk of dementia. METHODS: A total of 1,349 Japanese community residents aged 60 and older without dementia were followed prospectively for 10 years (2002-2012). Serum sTREM2 levels were quantified by using an enzyme-linked immunosorbent assay and divided into quartiles. Cox proportional hazards model was used to estimate the hazard ratios (HRs) of serum sTREM2 levels on the risk of dementia. RESULTS: During the follow-up, 300 subjects developed all-cause dementia; 193 had Alzheimer's disease (AD), and 85 had vascular dementia (VaD). The age- and sex-adjusted incidences of all-cause dementia, AD, and VaD elevated significantly with higher serum sTREM2 levels (all p for trend < 0.012). These associations were not altered after adjustment for confounding factors, including high-sensitive C-reactive protein. Subjects with the highest quartile of serum sTREM2 levels had significantly higher multivariable-adjusted risks of developing all-cause dementia, AD, and VaD than those with the lowest quartile (HR = 2.03, 95% confidence interval [CI] = 1.39-2.97, p < 0.001 for all-cause dementia; HR = 1.62, 95% CI = 1.02-2.55, p = 0.04 for AD; HR = 2.85, 95% CI = 1.35-6.02, p = 0.006 for VaD). No significant heterogeneity in the association of serum sTREM2 levels with the development of dementia was observed among the other risk factor subgroups (all p for heterogeneity > 0.11). INTERPRETATION: The present findings suggest a significant association between increased serum sTREM2 levels and the risk of developing all-cause dementia, AD, and VaD in the general elderly Japanese population. ANN NEUROL 2019;85:47-58.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Ohara T, Hata J, Tanaka M, et al. Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study. Ann Neurol. 2018. PMID: 30485483. doi:10.1002/ana.25385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。